AIGH Capital Management’s Aprea Therapeutics APRE Stock Holding History

AIGH Capital Management’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$815K	Hold	1,015,541	–	–	0.05%	42
2026 Q1	$775K	Buy	1,015,541 +645,000	+174%	+$507K	0.11%	40
2025 Q4	$316K	Sell	370,541 -168,759	-31%	-$207K	0.08%	34
2025 Q3	$795K	Hold	539,300	–	–	0.22%	37
2025 Q2	$913K	Hold	539,300	–	–	0.41%	28
2025 Q1	$1.1M	Hold	539,300	–	–	0.46%	35
2024 Q4	$1.77M	Hold	539,300	–	–	0.55%	28
2024 Q3	$1.48M	Hold	539,300	–	–	0.42%	30
2024 Q2	$2.19M	Hold	539,300	–	–	0.68%	24
2024 Q1	$3.5M	Buy	539,300 +190,000	+54%	+$1.18M	1.05%	27
2023 Q4	$1.64M	Hold	349,300	–	–	0.65%	32
2023 Q3	$1.46M	Hold	349,300	–	–	0.69%	35
2023 Q2	$1.1M	Buy	349,300 +4,300	+1%	+$16K	0.45%	39
2023 Q1	$1.53M	Buy	+345,000	New	+$2.55M	0.56%	37

Other funds holding APRE

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

AIGH Capital Management's APRE Position: Q2 2026 in Review

AIGH Capital Management held its Aprea Therapeutics (APRE) position steady in Q2 2026 at 1,015,541 shares worth $815K. The position accounts for 0.05% of the portfolio, ranked #42.

AIGH Capital Management first reported a position in APRE in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.5M in Q1 2024. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

AIGH Capital Management held 1,015,541 shares of Aprea Therapeutics worth $815K as of Q2 2026.
AIGH Capital Management left its Aprea Therapeutics share count unchanged in Q2 2026.
Aprea Therapeutics made up 0.05% of AIGH Capital Management's portfolio in Q2 2026, its #42 holding.
AIGH Capital Management first reported a position in Aprea Therapeutics in Q1 2023 and has held it in 14 quarters since.
AIGH Capital Management's Aprea Therapeutics position peaked at $3.5M in Q1 2024.
28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on AIGH Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.